Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 11/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9342406 | 0.79 | CYP1A2 (0.44) | BHMT | |
| SCHEMBL9342398 | 0.79 | CYP1A2 (0.44) | BHMT | |
| SCHEMBL4149894 | 0.79 | ALOX15 (0.43) | — | |
| SCHEMBL30731381 | 0.78 | RNPEP (0.37) | MARS1METAP2METAP1RNPEP | |
| SCHEMBL11119448 | 0.78 | NOS1 (0.43) | MARS1HSD17B10METAP2METAP1RNPEP | |
| SCHEMBL7157725 | 0.78 | NOS1 (0.43) | MARS1HSD17B10METAP2METAP1RNPEP | |
| SCHEMBL5211511 | 0.78 | NOS1 (0.43) | MARS1HSD17B10METAP2METAP1RNPEP | |
| Hydrochloric Acid SCHEMBL5211496 | 0.77 | NOS1 (0.42) | MARS1HSD17B10METAP2METAP1RNPEP | |
| Hydrochloric Acid SCHEMBL918798 | 0.77 | NOS1 (0.42) | MARS1HSD17B10METAP2METAP1RNPEP | |
| SCHEMBL4147433 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | ACTIVOTEC SPP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | RNGTT, CPSF7, CPSF1 | MARS1 798/4885HSD17B10 4567/4885METAP2 391/4885 |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | CPSF1, CPSF7, MAX | MARS1 216/4885HSD17B10 4651/4885METAP2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.